nodes	percent_of_prediction	percent_of_DWPC	metapath
Etoricoxib—Vismodegib—Sorafenib—liver cancer	0.424	1	CrCrCtD
Etoricoxib—MAPK14—liver cancer	0.337	0.844	CbGaD
Etoricoxib—CYP2E1—liver cancer	0.0624	0.156	CbGaD
Etoricoxib—CYP2C19—Sorafenib—liver cancer	0.0126	0.21	CbGbCtD
Etoricoxib—CYP1A2—Sorafenib—liver cancer	0.0116	0.194	CbGbCtD
Etoricoxib—CYP2C9—Sorafenib—liver cancer	0.0104	0.175	CbGbCtD
Etoricoxib—CYP2D6—Sorafenib—liver cancer	0.00955	0.16	CbGbCtD
Etoricoxib—CYP3A4—Sorafenib—liver cancer	0.00607	0.102	CbGbCtD
Etoricoxib—CYP2D6—Doxorubicin—liver cancer	0.0058	0.0971	CbGbCtD
Etoricoxib—CYP3A4—Doxorubicin—liver cancer	0.00369	0.0617	CbGbCtD
Etoricoxib—Vemurafenib—RAF1—liver cancer	0.00138	0.364	CrCbGaD
Etoricoxib—Celecoxib—MAPK14—liver cancer	0.00107	0.282	CrCbGaD
Etoricoxib—Vemurafenib—BRAF—liver cancer	0.000959	0.252	CrCbGaD
Etoricoxib—Vemurafenib—ALB—liver cancer	0.000186	0.0489	CrCbGaD
Etoricoxib—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000137	0.0026	CcSEcCtD
Etoricoxib—Blood urea increased—Doxorubicin—liver cancer	0.000136	0.00258	CcSEcCtD
Etoricoxib—Vaginal infection—Doxorubicin—liver cancer	0.000136	0.00258	CcSEcCtD
Etoricoxib—Neuropathy—Doxorubicin—liver cancer	0.000135	0.00256	CcSEcCtD
Etoricoxib—Dyspnoea—Sorafenib—liver cancer	0.000134	0.00254	CcSEcCtD
Etoricoxib—Dyspepsia—Sorafenib—liver cancer	0.000132	0.00251	CcSEcCtD
Etoricoxib—Decreased appetite—Sorafenib—liver cancer	0.000131	0.00248	CcSEcCtD
Etoricoxib—Mouth ulceration—Doxorubicin—liver cancer	0.00013	0.00247	CcSEcCtD
Etoricoxib—Bladder pain—Doxorubicin—liver cancer	0.00013	0.00247	CcSEcCtD
Etoricoxib—Neoplasm—Doxorubicin—liver cancer	0.00013	0.00247	CcSEcCtD
Etoricoxib—Ecchymosis—Doxorubicin—liver cancer	0.00013	0.00247	CcSEcCtD
Etoricoxib—Diabetes mellitus—Epirubicin—liver cancer	0.00013	0.00246	CcSEcCtD
Etoricoxib—Blood alkaline phosphatase increased—Epirubicin—liver cancer	0.00013	0.00246	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Sorafenib—liver cancer	0.00013	0.00246	CcSEcCtD
Etoricoxib—Fatigue—Sorafenib—liver cancer	0.00013	0.00246	CcSEcCtD
Etoricoxib—Constipation—Sorafenib—liver cancer	0.000129	0.00244	CcSEcCtD
Etoricoxib—Pain—Sorafenib—liver cancer	0.000129	0.00244	CcSEcCtD
Etoricoxib—Eczema—Epirubicin—liver cancer	0.000126	0.00238	CcSEcCtD
Etoricoxib—Hepatic failure—Epirubicin—liver cancer	0.000126	0.00238	CcSEcCtD
Etoricoxib—Cardiac failure congestive—Epirubicin—liver cancer	0.000125	0.00236	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Sorafenib—liver cancer	0.000123	0.00233	CcSEcCtD
Etoricoxib—Diabetes mellitus—Doxorubicin—liver cancer	0.00012	0.00228	CcSEcCtD
Etoricoxib—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.00012	0.00228	CcSEcCtD
Etoricoxib—Urticaria—Sorafenib—liver cancer	0.000119	0.00226	CcSEcCtD
Etoricoxib—Abdominal pain—Sorafenib—liver cancer	0.000119	0.00225	CcSEcCtD
Etoricoxib—Renal impairment—Epirubicin—liver cancer	0.000119	0.00225	CcSEcCtD
Etoricoxib—Anaphylactoid reaction—Epirubicin—liver cancer	0.000117	0.00221	CcSEcCtD
Etoricoxib—Eczema—Doxorubicin—liver cancer	0.000116	0.00221	CcSEcCtD
Etoricoxib—Hepatic failure—Doxorubicin—liver cancer	0.000116	0.00221	CcSEcCtD
Etoricoxib—Cerebrovascular accident—Epirubicin—liver cancer	0.000115	0.00219	CcSEcCtD
Etoricoxib—Cardiac failure congestive—Doxorubicin—liver cancer	0.000115	0.00219	CcSEcCtD
Etoricoxib—Pain in extremity—Epirubicin—liver cancer	0.000113	0.00214	CcSEcCtD
Etoricoxib—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.000113	0.00214	CcSEcCtD
Etoricoxib—Hypersensitivity—Sorafenib—liver cancer	0.000111	0.0021	CcSEcCtD
Etoricoxib—Renal impairment—Doxorubicin—liver cancer	0.00011	0.00208	CcSEcCtD
Etoricoxib—Celecoxib—ALB—liver cancer	0.000109	0.0287	CrCbGaD
Etoricoxib—Anaphylactoid reaction—Doxorubicin—liver cancer	0.000108	0.00205	CcSEcCtD
Etoricoxib—Asthenia—Sorafenib—liver cancer	0.000108	0.00204	CcSEcCtD
Etoricoxib—Cardiac arrest—Epirubicin—liver cancer	0.000107	0.00204	CcSEcCtD
Etoricoxib—Cerebrovascular accident—Doxorubicin—liver cancer	0.000107	0.00202	CcSEcCtD
Etoricoxib—Pruritus—Sorafenib—liver cancer	0.000106	0.00202	CcSEcCtD
Etoricoxib—Blood creatinine increased—Epirubicin—liver cancer	0.000106	0.00201	CcSEcCtD
Etoricoxib—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.000105	0.00198	CcSEcCtD
Etoricoxib—Pain in extremity—Doxorubicin—liver cancer	0.000105	0.00198	CcSEcCtD
Etoricoxib—Orthostatic hypotension—Epirubicin—liver cancer	0.000103	0.00196	CcSEcCtD
Etoricoxib—Diarrhoea—Sorafenib—liver cancer	0.000103	0.00195	CcSEcCtD
Etoricoxib—Breast disorder—Epirubicin—liver cancer	0.000102	0.00194	CcSEcCtD
Etoricoxib—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.000102	0.00193	CcSEcCtD
Etoricoxib—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000102	0.00193	CcSEcCtD
Etoricoxib—Gastritis—Epirubicin—liver cancer	0.0001	0.0019	CcSEcCtD
Etoricoxib—Alanine aminotransferase increased—Epirubicin—liver cancer	9.97e-05	0.00189	CcSEcCtD
Etoricoxib—Muscular weakness—Epirubicin—liver cancer	9.97e-05	0.00189	CcSEcCtD
Etoricoxib—Cardiac arrest—Doxorubicin—liver cancer	9.94e-05	0.00189	CcSEcCtD
Etoricoxib—Dizziness—Sorafenib—liver cancer	9.94e-05	0.00188	CcSEcCtD
Etoricoxib—Abdominal distension—Epirubicin—liver cancer	9.83e-05	0.00186	CcSEcCtD
Etoricoxib—Blood creatinine increased—Doxorubicin—liver cancer	9.8e-05	0.00186	CcSEcCtD
Etoricoxib—Pancreatitis—Epirubicin—liver cancer	9.58e-05	0.00182	CcSEcCtD
Etoricoxib—Vomiting—Sorafenib—liver cancer	9.56e-05	0.00181	CcSEcCtD
Etoricoxib—Orthostatic hypotension—Doxorubicin—liver cancer	9.55e-05	0.00181	CcSEcCtD
Etoricoxib—Angina pectoris—Epirubicin—liver cancer	9.51e-05	0.0018	CcSEcCtD
Etoricoxib—Rash—Sorafenib—liver cancer	9.48e-05	0.0018	CcSEcCtD
Etoricoxib—Dermatitis—Sorafenib—liver cancer	9.47e-05	0.0018	CcSEcCtD
Etoricoxib—Breast disorder—Doxorubicin—liver cancer	9.45e-05	0.00179	CcSEcCtD
Etoricoxib—Toxic epidermal necrolysis—Doxorubicin—liver cancer	9.42e-05	0.00179	CcSEcCtD
Etoricoxib—Aspartate aminotransferase increased—Doxorubicin—liver cancer	9.42e-05	0.00179	CcSEcCtD
Etoricoxib—Headache—Sorafenib—liver cancer	9.42e-05	0.00179	CcSEcCtD
Etoricoxib—Bronchitis—Epirubicin—liver cancer	9.39e-05	0.00178	CcSEcCtD
Etoricoxib—Vismodegib—ALB—liver cancer	9.36e-05	0.0246	CrCbGaD
Etoricoxib—Gastritis—Doxorubicin—liver cancer	9.25e-05	0.00175	CcSEcCtD
Etoricoxib—Muscular weakness—Doxorubicin—liver cancer	9.22e-05	0.00175	CcSEcCtD
Etoricoxib—Alanine aminotransferase increased—Doxorubicin—liver cancer	9.22e-05	0.00175	CcSEcCtD
Etoricoxib—Abdominal distension—Doxorubicin—liver cancer	9.1e-05	0.00173	CcSEcCtD
Etoricoxib—Upper respiratory tract infection—Epirubicin—liver cancer	9.08e-05	0.00172	CcSEcCtD
Etoricoxib—Nausea—Sorafenib—liver cancer	8.93e-05	0.00169	CcSEcCtD
Etoricoxib—Photosensitivity reaction—Epirubicin—liver cancer	8.92e-05	0.00169	CcSEcCtD
Etoricoxib—Weight increased—Epirubicin—liver cancer	8.89e-05	0.00169	CcSEcCtD
Etoricoxib—Pancreatitis—Doxorubicin—liver cancer	8.86e-05	0.00168	CcSEcCtD
Etoricoxib—Hyperglycaemia—Epirubicin—liver cancer	8.81e-05	0.00167	CcSEcCtD
Etoricoxib—Angina pectoris—Doxorubicin—liver cancer	8.8e-05	0.00167	CcSEcCtD
Etoricoxib—Pneumonia—Epirubicin—liver cancer	8.76e-05	0.00166	CcSEcCtD
Etoricoxib—Infestation NOS—Epirubicin—liver cancer	8.71e-05	0.00165	CcSEcCtD
Etoricoxib—Infestation—Epirubicin—liver cancer	8.71e-05	0.00165	CcSEcCtD
Etoricoxib—Bronchitis—Doxorubicin—liver cancer	8.69e-05	0.00165	CcSEcCtD
Etoricoxib—Stevens-Johnson syndrome—Epirubicin—liver cancer	8.63e-05	0.00164	CcSEcCtD
Etoricoxib—Renal failure—Epirubicin—liver cancer	8.56e-05	0.00162	CcSEcCtD
Etoricoxib—Neuropathy peripheral—Epirubicin—liver cancer	8.54e-05	0.00162	CcSEcCtD
Etoricoxib—Stomatitis—Epirubicin—liver cancer	8.49e-05	0.00161	CcSEcCtD
Etoricoxib—Jaundice—Epirubicin—liver cancer	8.49e-05	0.00161	CcSEcCtD
Etoricoxib—Urinary tract infection—Epirubicin—liver cancer	8.47e-05	0.00161	CcSEcCtD
Etoricoxib—Conjunctivitis—Epirubicin—liver cancer	8.47e-05	0.00161	CcSEcCtD
Etoricoxib—Upper respiratory tract infection—Doxorubicin—liver cancer	8.4e-05	0.00159	CcSEcCtD
Etoricoxib—Haematuria—Epirubicin—liver cancer	8.3e-05	0.00157	CcSEcCtD
Etoricoxib—Photosensitivity reaction—Doxorubicin—liver cancer	8.25e-05	0.00156	CcSEcCtD
Etoricoxib—Hepatobiliary disease—Epirubicin—liver cancer	8.24e-05	0.00156	CcSEcCtD
Etoricoxib—Weight increased—Doxorubicin—liver cancer	8.22e-05	0.00156	CcSEcCtD
Etoricoxib—Epistaxis—Epirubicin—liver cancer	8.21e-05	0.00156	CcSEcCtD
Etoricoxib—Sinusitis—Epirubicin—liver cancer	8.17e-05	0.00155	CcSEcCtD
Etoricoxib—Hyperglycaemia—Doxorubicin—liver cancer	8.15e-05	0.00155	CcSEcCtD
Etoricoxib—Pneumonia—Doxorubicin—liver cancer	8.1e-05	0.00154	CcSEcCtD
Etoricoxib—Infestation NOS—Doxorubicin—liver cancer	8.06e-05	0.00153	CcSEcCtD
Etoricoxib—Infestation—Doxorubicin—liver cancer	8.06e-05	0.00153	CcSEcCtD
Etoricoxib—Stevens-Johnson syndrome—Doxorubicin—liver cancer	7.99e-05	0.00152	CcSEcCtD
Etoricoxib—Renal failure—Doxorubicin—liver cancer	7.92e-05	0.0015	CcSEcCtD
Etoricoxib—Neuropathy peripheral—Doxorubicin—liver cancer	7.9e-05	0.0015	CcSEcCtD
Etoricoxib—Haemoglobin—Epirubicin—liver cancer	7.86e-05	0.00149	CcSEcCtD
Etoricoxib—Stomatitis—Doxorubicin—liver cancer	7.85e-05	0.00149	CcSEcCtD
Etoricoxib—Jaundice—Doxorubicin—liver cancer	7.85e-05	0.00149	CcSEcCtD
Etoricoxib—Conjunctivitis—Doxorubicin—liver cancer	7.83e-05	0.00149	CcSEcCtD
Etoricoxib—Urinary tract infection—Doxorubicin—liver cancer	7.83e-05	0.00149	CcSEcCtD
Etoricoxib—Haemorrhage—Epirubicin—liver cancer	7.82e-05	0.00148	CcSEcCtD
Etoricoxib—Hepatitis—Epirubicin—liver cancer	7.82e-05	0.00148	CcSEcCtD
Etoricoxib—Hypoaesthesia—Epirubicin—liver cancer	7.78e-05	0.00148	CcSEcCtD
Etoricoxib—Pharyngitis—Epirubicin—liver cancer	7.76e-05	0.00147	CcSEcCtD
Etoricoxib—Urinary tract disorder—Epirubicin—liver cancer	7.72e-05	0.00146	CcSEcCtD
Etoricoxib—Oedema peripheral—Epirubicin—liver cancer	7.7e-05	0.00146	CcSEcCtD
Etoricoxib—Haematuria—Doxorubicin—liver cancer	7.68e-05	0.00146	CcSEcCtD
Etoricoxib—Connective tissue disorder—Epirubicin—liver cancer	7.68e-05	0.00146	CcSEcCtD
Etoricoxib—Urethral disorder—Epirubicin—liver cancer	7.66e-05	0.00145	CcSEcCtD
Etoricoxib—Hepatobiliary disease—Doxorubicin—liver cancer	7.62e-05	0.00145	CcSEcCtD
Etoricoxib—Epistaxis—Doxorubicin—liver cancer	7.6e-05	0.00144	CcSEcCtD
Etoricoxib—Sinusitis—Doxorubicin—liver cancer	7.56e-05	0.00143	CcSEcCtD
Etoricoxib—Visual impairment—Epirubicin—liver cancer	7.53e-05	0.00143	CcSEcCtD
Etoricoxib—Erythema multiforme—Epirubicin—liver cancer	7.39e-05	0.0014	CcSEcCtD
Etoricoxib—Eye disorder—Epirubicin—liver cancer	7.31e-05	0.00139	CcSEcCtD
Etoricoxib—Tinnitus—Epirubicin—liver cancer	7.29e-05	0.00138	CcSEcCtD
Etoricoxib—Haemoglobin—Doxorubicin—liver cancer	7.27e-05	0.00138	CcSEcCtD
Etoricoxib—Flushing—Epirubicin—liver cancer	7.26e-05	0.00138	CcSEcCtD
Etoricoxib—Cardiac disorder—Epirubicin—liver cancer	7.26e-05	0.00138	CcSEcCtD
Etoricoxib—Haemorrhage—Doxorubicin—liver cancer	7.23e-05	0.00137	CcSEcCtD
Etoricoxib—Hepatitis—Doxorubicin—liver cancer	7.23e-05	0.00137	CcSEcCtD
Etoricoxib—Hypoaesthesia—Doxorubicin—liver cancer	7.2e-05	0.00136	CcSEcCtD
Etoricoxib—Pharyngitis—Doxorubicin—liver cancer	7.18e-05	0.00136	CcSEcCtD
Etoricoxib—Urinary tract disorder—Doxorubicin—liver cancer	7.14e-05	0.00135	CcSEcCtD
Etoricoxib—Oedema peripheral—Doxorubicin—liver cancer	7.13e-05	0.00135	CcSEcCtD
Etoricoxib—Connective tissue disorder—Doxorubicin—liver cancer	7.11e-05	0.00135	CcSEcCtD
Etoricoxib—Angiopathy—Epirubicin—liver cancer	7.09e-05	0.00135	CcSEcCtD
Etoricoxib—Urethral disorder—Doxorubicin—liver cancer	7.09e-05	0.00134	CcSEcCtD
Etoricoxib—Immune system disorder—Epirubicin—liver cancer	7.06e-05	0.00134	CcSEcCtD
Etoricoxib—Mediastinal disorder—Epirubicin—liver cancer	7.05e-05	0.00134	CcSEcCtD
Etoricoxib—Arrhythmia—Epirubicin—liver cancer	6.98e-05	0.00132	CcSEcCtD
Etoricoxib—Visual impairment—Doxorubicin—liver cancer	6.97e-05	0.00132	CcSEcCtD
Etoricoxib—Alopecia—Epirubicin—liver cancer	6.91e-05	0.00131	CcSEcCtD
Etoricoxib—Mental disorder—Epirubicin—liver cancer	6.85e-05	0.0013	CcSEcCtD
Etoricoxib—Erythema multiforme—Doxorubicin—liver cancer	6.84e-05	0.0013	CcSEcCtD
Etoricoxib—Malnutrition—Epirubicin—liver cancer	6.81e-05	0.00129	CcSEcCtD
Etoricoxib—Erythema—Epirubicin—liver cancer	6.81e-05	0.00129	CcSEcCtD
Etoricoxib—Eye disorder—Doxorubicin—liver cancer	6.76e-05	0.00128	CcSEcCtD
Etoricoxib—Tinnitus—Doxorubicin—liver cancer	6.74e-05	0.00128	CcSEcCtD
Etoricoxib—Flushing—Doxorubicin—liver cancer	6.71e-05	0.00127	CcSEcCtD
Etoricoxib—Cardiac disorder—Doxorubicin—liver cancer	6.71e-05	0.00127	CcSEcCtD
Etoricoxib—Flatulence—Epirubicin—liver cancer	6.71e-05	0.00127	CcSEcCtD
Etoricoxib—Dysgeusia—Epirubicin—liver cancer	6.66e-05	0.00126	CcSEcCtD
Etoricoxib—Angiopathy—Doxorubicin—liver cancer	6.56e-05	0.00124	CcSEcCtD
Etoricoxib—Muscle spasms—Epirubicin—liver cancer	6.54e-05	0.00124	CcSEcCtD
Etoricoxib—Immune system disorder—Doxorubicin—liver cancer	6.53e-05	0.00124	CcSEcCtD
Etoricoxib—Mediastinal disorder—Doxorubicin—liver cancer	6.52e-05	0.00124	CcSEcCtD
Etoricoxib—Arrhythmia—Doxorubicin—liver cancer	6.46e-05	0.00123	CcSEcCtD
Etoricoxib—Vision blurred—Epirubicin—liver cancer	6.41e-05	0.00122	CcSEcCtD
Etoricoxib—Alopecia—Doxorubicin—liver cancer	6.39e-05	0.00121	CcSEcCtD
Etoricoxib—Mental disorder—Doxorubicin—liver cancer	6.34e-05	0.0012	CcSEcCtD
Etoricoxib—Malnutrition—Doxorubicin—liver cancer	6.3e-05	0.00119	CcSEcCtD
Etoricoxib—Erythema—Doxorubicin—liver cancer	6.3e-05	0.00119	CcSEcCtD
Etoricoxib—Anaemia—Epirubicin—liver cancer	6.29e-05	0.00119	CcSEcCtD
Etoricoxib—Agitation—Epirubicin—liver cancer	6.25e-05	0.00119	CcSEcCtD
Etoricoxib—Flatulence—Doxorubicin—liver cancer	6.21e-05	0.00118	CcSEcCtD
Etoricoxib—Dysgeusia—Doxorubicin—liver cancer	6.17e-05	0.00117	CcSEcCtD
Etoricoxib—Muscle spasms—Doxorubicin—liver cancer	6.05e-05	0.00115	CcSEcCtD
Etoricoxib—Palpitations—Epirubicin—liver cancer	6.01e-05	0.00114	CcSEcCtD
Etoricoxib—Cough—Epirubicin—liver cancer	5.94e-05	0.00113	CcSEcCtD
Etoricoxib—Vision blurred—Doxorubicin—liver cancer	5.93e-05	0.00113	CcSEcCtD
Etoricoxib—Hypertension—Epirubicin—liver cancer	5.88e-05	0.00111	CcSEcCtD
Etoricoxib—Anaemia—Doxorubicin—liver cancer	5.82e-05	0.0011	CcSEcCtD
Etoricoxib—Arthralgia—Epirubicin—liver cancer	5.79e-05	0.0011	CcSEcCtD
Etoricoxib—Chest pain—Epirubicin—liver cancer	5.79e-05	0.0011	CcSEcCtD
Etoricoxib—Agitation—Doxorubicin—liver cancer	5.79e-05	0.0011	CcSEcCtD
Etoricoxib—Anxiety—Epirubicin—liver cancer	5.77e-05	0.00109	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	5.75e-05	0.00109	CcSEcCtD
Etoricoxib—Dry mouth—Epirubicin—liver cancer	5.67e-05	0.00107	CcSEcCtD
Etoricoxib—Confusional state—Epirubicin—liver cancer	5.6e-05	0.00106	CcSEcCtD
Etoricoxib—Palpitations—Doxorubicin—liver cancer	5.56e-05	0.00106	CcSEcCtD
Etoricoxib—Oedema—Epirubicin—liver cancer	5.55e-05	0.00105	CcSEcCtD
Etoricoxib—Anaphylactic shock—Epirubicin—liver cancer	5.55e-05	0.00105	CcSEcCtD
Etoricoxib—Infection—Epirubicin—liver cancer	5.52e-05	0.00105	CcSEcCtD
Etoricoxib—Cough—Doxorubicin—liver cancer	5.5e-05	0.00104	CcSEcCtD
Etoricoxib—Shock—Epirubicin—liver cancer	5.46e-05	0.00104	CcSEcCtD
Etoricoxib—Nervous system disorder—Epirubicin—liver cancer	5.45e-05	0.00103	CcSEcCtD
Etoricoxib—Thrombocytopenia—Epirubicin—liver cancer	5.44e-05	0.00103	CcSEcCtD
Etoricoxib—Hypertension—Doxorubicin—liver cancer	5.44e-05	0.00103	CcSEcCtD
Etoricoxib—Skin disorder—Epirubicin—liver cancer	5.4e-05	0.00102	CcSEcCtD
Etoricoxib—Chest pain—Doxorubicin—liver cancer	5.36e-05	0.00102	CcSEcCtD
Etoricoxib—Arthralgia—Doxorubicin—liver cancer	5.36e-05	0.00102	CcSEcCtD
Etoricoxib—Anxiety—Doxorubicin—liver cancer	5.34e-05	0.00101	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	5.32e-05	0.00101	CcSEcCtD
Etoricoxib—Anorexia—Epirubicin—liver cancer	5.29e-05	0.001	CcSEcCtD
Etoricoxib—Dry mouth—Doxorubicin—liver cancer	5.24e-05	0.000994	CcSEcCtD
Etoricoxib—Confusional state—Doxorubicin—liver cancer	5.18e-05	0.000983	CcSEcCtD
Etoricoxib—Anaphylactic shock—Doxorubicin—liver cancer	5.14e-05	0.000975	CcSEcCtD
Etoricoxib—Oedema—Doxorubicin—liver cancer	5.14e-05	0.000975	CcSEcCtD
Etoricoxib—Infection—Doxorubicin—liver cancer	5.11e-05	0.000968	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Epirubicin—liver cancer	5.06e-05	0.00096	CcSEcCtD
Etoricoxib—Shock—Doxorubicin—liver cancer	5.06e-05	0.000959	CcSEcCtD
Etoricoxib—Nervous system disorder—Doxorubicin—liver cancer	5.04e-05	0.000956	CcSEcCtD
Etoricoxib—Thrombocytopenia—Doxorubicin—liver cancer	5.03e-05	0.000954	CcSEcCtD
Etoricoxib—Insomnia—Epirubicin—liver cancer	5.02e-05	0.000953	CcSEcCtD
Etoricoxib—Skin disorder—Doxorubicin—liver cancer	4.99e-05	0.000947	CcSEcCtD
Etoricoxib—Dyspnoea—Epirubicin—liver cancer	4.95e-05	0.000939	CcSEcCtD
Etoricoxib—Somnolence—Epirubicin—liver cancer	4.94e-05	0.000936	CcSEcCtD
Etoricoxib—Anorexia—Doxorubicin—liver cancer	4.9e-05	0.000929	CcSEcCtD
Etoricoxib—Dyspepsia—Epirubicin—liver cancer	4.89e-05	0.000927	CcSEcCtD
Etoricoxib—Decreased appetite—Epirubicin—liver cancer	4.83e-05	0.000916	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Epirubicin—liver cancer	4.8e-05	0.000909	CcSEcCtD
Etoricoxib—Fatigue—Epirubicin—liver cancer	4.79e-05	0.000908	CcSEcCtD
Etoricoxib—Pain—Epirubicin—liver cancer	4.75e-05	0.000901	CcSEcCtD
Etoricoxib—Constipation—Epirubicin—liver cancer	4.75e-05	0.000901	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Doxorubicin—liver cancer	4.68e-05	0.000888	CcSEcCtD
Etoricoxib—Insomnia—Doxorubicin—liver cancer	4.65e-05	0.000881	CcSEcCtD
Etoricoxib—Dyspnoea—Doxorubicin—liver cancer	4.58e-05	0.000869	CcSEcCtD
Etoricoxib—Feeling abnormal—Epirubicin—liver cancer	4.58e-05	0.000868	CcSEcCtD
Etoricoxib—Somnolence—Doxorubicin—liver cancer	4.57e-05	0.000866	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Epirubicin—liver cancer	4.54e-05	0.000861	CcSEcCtD
Etoricoxib—Dyspepsia—Doxorubicin—liver cancer	4.52e-05	0.000858	CcSEcCtD
Etoricoxib—Decreased appetite—Doxorubicin—liver cancer	4.47e-05	0.000847	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Doxorubicin—liver cancer	4.44e-05	0.000841	CcSEcCtD
Etoricoxib—Fatigue—Doxorubicin—liver cancer	4.43e-05	0.00084	CcSEcCtD
Etoricoxib—Urticaria—Epirubicin—liver cancer	4.41e-05	0.000837	CcSEcCtD
Etoricoxib—Pain—Doxorubicin—liver cancer	4.39e-05	0.000833	CcSEcCtD
Etoricoxib—Constipation—Doxorubicin—liver cancer	4.39e-05	0.000833	CcSEcCtD
Etoricoxib—Abdominal pain—Epirubicin—liver cancer	4.39e-05	0.000833	CcSEcCtD
Etoricoxib—Feeling abnormal—Doxorubicin—liver cancer	4.24e-05	0.000803	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Doxorubicin—liver cancer	4.2e-05	0.000797	CcSEcCtD
Etoricoxib—Hypersensitivity—Epirubicin—liver cancer	4.09e-05	0.000776	CcSEcCtD
Etoricoxib—Urticaria—Doxorubicin—liver cancer	4.08e-05	0.000774	CcSEcCtD
Etoricoxib—Abdominal pain—Doxorubicin—liver cancer	4.06e-05	0.00077	CcSEcCtD
Etoricoxib—Asthenia—Epirubicin—liver cancer	3.99e-05	0.000756	CcSEcCtD
Etoricoxib—Pruritus—Epirubicin—liver cancer	3.93e-05	0.000745	CcSEcCtD
Etoricoxib—Diarrhoea—Epirubicin—liver cancer	3.8e-05	0.000721	CcSEcCtD
Etoricoxib—Hypersensitivity—Doxorubicin—liver cancer	3.79e-05	0.000718	CcSEcCtD
Etoricoxib—Asthenia—Doxorubicin—liver cancer	3.69e-05	0.000699	CcSEcCtD
Etoricoxib—Dizziness—Epirubicin—liver cancer	3.67e-05	0.000697	CcSEcCtD
Etoricoxib—Pruritus—Doxorubicin—liver cancer	3.64e-05	0.00069	CcSEcCtD
Etoricoxib—Vomiting—Epirubicin—liver cancer	3.53e-05	0.00067	CcSEcCtD
Etoricoxib—Diarrhoea—Doxorubicin—liver cancer	3.52e-05	0.000667	CcSEcCtD
Etoricoxib—Rash—Epirubicin—liver cancer	3.5e-05	0.000664	CcSEcCtD
Etoricoxib—Dermatitis—Epirubicin—liver cancer	3.5e-05	0.000664	CcSEcCtD
Etoricoxib—Headache—Epirubicin—liver cancer	3.48e-05	0.00066	CcSEcCtD
Etoricoxib—Dizziness—Doxorubicin—liver cancer	3.4e-05	0.000644	CcSEcCtD
Etoricoxib—Nausea—Epirubicin—liver cancer	3.3e-05	0.000626	CcSEcCtD
Etoricoxib—Vomiting—Doxorubicin—liver cancer	3.27e-05	0.00062	CcSEcCtD
Etoricoxib—Rash—Doxorubicin—liver cancer	3.24e-05	0.000615	CcSEcCtD
Etoricoxib—Dermatitis—Doxorubicin—liver cancer	3.24e-05	0.000614	CcSEcCtD
Etoricoxib—Headache—Doxorubicin—liver cancer	3.22e-05	0.000611	CcSEcCtD
Etoricoxib—Nausea—Doxorubicin—liver cancer	3.05e-05	0.000579	CcSEcCtD
Etoricoxib—CYP1A2—Metabolism—GSTA4—liver cancer	5.03e-06	8.27e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CRABP1—liver cancer	5e-06	8.22e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—GGT1—liver cancer	4.94e-06	8.13e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—GOT1—liver cancer	4.94e-06	8.13e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	4.94e-06	8.12e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—IL6—liver cancer	4.93e-06	8.11e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—PIK3CA—liver cancer	4.92e-06	8.09e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	4.92e-06	8.08e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GSTA2—liver cancer	4.9e-06	8.06e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—RAF1—liver cancer	4.81e-06	7.91e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—HPGDS—liver cancer	4.8e-06	7.88e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—liver cancer	4.77e-06	7.84e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—H2AFX—liver cancer	4.75e-06	7.8e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—CYCS—liver cancer	4.74e-06	7.79e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GSTA1—liver cancer	4.73e-06	7.77e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TERT—liver cancer	4.71e-06	7.74e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—MTOR—liver cancer	4.7e-06	7.73e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—PIK3CB—liver cancer	4.7e-06	7.73e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—NAT2—liver cancer	4.68e-06	7.68e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—GGT1—liver cancer	4.65e-06	7.65e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—GOT1—liver cancer	4.65e-06	7.65e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—HRAS—liver cancer	4.55e-06	7.48e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—AKT1—liver cancer	4.55e-06	7.48e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	4.51e-06	7.41e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	4.5e-06	7.39e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ALDOB—liver cancer	4.48e-06	7.37e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CPT1B—liver cancer	4.48e-06	7.36e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GLUL—liver cancer	4.48e-06	7.36e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—AKT1—liver cancer	4.46e-06	7.34e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—GSTP1—liver cancer	4.44e-06	7.3e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—HPGDS—liver cancer	4.41e-06	7.25e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CDKN1B—liver cancer	4.41e-06	7.25e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—HMOX1—liver cancer	4.38e-06	7.2e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—HPGDS—liver cancer	4.37e-06	7.19e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—IL6—liver cancer	4.36e-06	7.16e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	4.35e-06	7.15e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	4.34e-06	7.14e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—NR1H4—liver cancer	4.32e-06	7.09e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IL2—liver cancer	4.32e-06	7.09e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MTHFR—liver cancer	4.31e-06	7.08e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—KDR—liver cancer	4.31e-06	7.08e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—TERT—liver cancer	4.29e-06	7.06e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—liver cancer	4.29e-06	7.05e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CRABP1—liver cancer	4.28e-06	7.03e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PSMD10—liver cancer	4.28e-06	7.03e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PSMA4—liver cancer	4.28e-06	7.03e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GSTA3—liver cancer	4.24e-06	6.98e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—JUN—liver cancer	4.2e-06	6.9e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—ESR1—liver cancer	4.2e-06	6.9e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—GSTP1—liver cancer	4.18e-06	6.87e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CTNNB1—liver cancer	4.17e-06	6.85e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GOT2—liver cancer	4.16e-06	6.84e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—F2—liver cancer	4.14e-06	6.81e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—HMOX1—liver cancer	4.12e-06	6.78e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—GSTM1—liver cancer	4.08e-06	6.71e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CDKN1A—liver cancer	4.07e-06	6.69e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—AKT1—liver cancer	4.02e-06	6.61e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—MAPK8—liver cancer	3.97e-06	6.53e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PIK3CG—liver cancer	3.97e-06	6.52e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—APC—liver cancer	3.97e-06	6.52e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	3.96e-06	6.51e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PSMA4—liver cancer	3.93e-06	6.46e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PSMD10—liver cancer	3.93e-06	6.46e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CYP2E1—liver cancer	3.91e-06	6.43e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	3.91e-06	6.43e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PSMA4—liver cancer	3.9e-06	6.41e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PSMD10—liver cancer	3.9e-06	6.41e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GSTA4—liver cancer	3.88e-06	6.38e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—CYP1A1—liver cancer	3.87e-06	6.36e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	3.85e-06	6.33e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—GSTM1—liver cancer	3.84e-06	6.31e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GOT2—liver cancer	3.83e-06	6.29e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GOT2—liver cancer	3.79e-06	6.23e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	3.79e-06	6.22e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GSTA2—liver cancer	3.78e-06	6.22e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—HPGDS—liver cancer	3.74e-06	6.14e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—BRAF—liver cancer	3.73e-06	6.13e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	3.72e-06	6.11e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CYCS—liver cancer	3.66e-06	6.01e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GSTA1—liver cancer	3.65e-06	6e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—CYP1A1—liver cancer	3.64e-06	5.99e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—STAT3—liver cancer	3.63e-06	5.97e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—APC—liver cancer	3.62e-06	5.95e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—NAT2—liver cancer	3.61e-06	5.93e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—MTHFR—liver cancer	3.61e-06	5.93e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CYP2E1—liver cancer	3.6e-06	5.91e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GOT1—liver cancer	3.59e-06	5.9e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GGT1—liver cancer	3.59e-06	5.9e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CYP2E1—liver cancer	3.57e-06	5.86e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PPARA—liver cancer	3.54e-06	5.82e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PIK3CD—liver cancer	3.49e-06	5.73e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ALDOB—liver cancer	3.46e-06	5.69e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	3.45e-06	5.67e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—SERPINE1—liver cancer	3.45e-06	5.67e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—BRAF—liver cancer	3.4e-06	5.59e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—MTHFR—liver cancer	3.4e-06	5.58e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	3.39e-06	5.56e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CYCS—liver cancer	3.37e-06	5.53e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—MYC—liver cancer	3.36e-06	5.52e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	3.34e-06	5.49e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CYCS—liver cancer	3.34e-06	5.48e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PSMA4—liver cancer	3.33e-06	5.48e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PSMD10—liver cancer	3.33e-06	5.48e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PPARA—liver cancer	3.33e-06	5.47e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GGT1—liver cancer	3.3e-06	5.43e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GOT1—liver cancer	3.3e-06	5.43e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CRABP1—liver cancer	3.3e-06	5.42e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GGT1—liver cancer	3.27e-06	5.38e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GOT1—liver cancer	3.27e-06	5.38e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GOT2—liver cancer	3.24e-06	5.33e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GSTP1—liver cancer	3.23e-06	5.3e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PIK3CD—liver cancer	3.18e-06	5.23e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—HMOX1—liver cancer	3.18e-06	5.23e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.18e-06	5.22e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—SERPINE1—liver cancer	3.15e-06	5.17e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—KRAS—liver cancer	3.12e-06	5.13e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—RAF1—liver cancer	3.11e-06	5.12e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CYP2E1—liver cancer	3.05e-06	5.01e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PIK3CB—liver cancer	3.04e-06	4.99e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MTOR—liver cancer	3.04e-06	4.99e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CG—liver cancer	3.03e-06	4.98e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GSTP1—liver cancer	2.97e-06	4.88e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GSTM1—liver cancer	2.96e-06	4.87e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	2.95e-06	4.85e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GSTP1—liver cancer	2.94e-06	4.83e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—HMOX1—liver cancer	2.93e-06	4.81e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PPARG—liver cancer	2.92e-06	4.81e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—HMOX1—liver cancer	2.9e-06	4.77e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—HPGDS—liver cancer	2.89e-06	4.74e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—PIK3CA—liver cancer	2.87e-06	4.71e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CG—liver cancer	2.85e-06	4.69e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CDKN1B—liver cancer	2.85e-06	4.69e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CYCS—liver cancer	2.85e-06	4.69e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—RAF1—liver cancer	2.84e-06	4.67e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CYP1A1—liver cancer	2.81e-06	4.62e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GGT1—liver cancer	2.8e-06	4.6e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GOT1—liver cancer	2.8e-06	4.6e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CASP3—liver cancer	2.8e-06	4.59e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—IL2—liver cancer	2.79e-06	4.59e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MTOR—liver cancer	2.77e-06	4.56e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PIK3CB—liver cancer	2.77e-06	4.56e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PPARG—liver cancer	2.75e-06	4.52e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GSTM1—liver cancer	2.73e-06	4.48e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CCND1—liver cancer	2.72e-06	4.47e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—JUN—liver cancer	2.72e-06	4.46e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GSTM1—liver cancer	2.7e-06	4.44e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CTNNB1—liver cancer	2.69e-06	4.43e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CD—liver cancer	2.66e-06	4.38e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—HRAS—liver cancer	2.65e-06	4.36e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MMP9—liver cancer	2.64e-06	4.34e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CDKN1A—liver cancer	2.63e-06	4.33e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—ALB—liver cancer	2.63e-06	4.32e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—MTHFR—liver cancer	2.62e-06	4.3e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CDKN1B—liver cancer	2.6e-06	4.28e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CYP1A1—liver cancer	2.58e-06	4.25e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PSMD10—liver cancer	2.57e-06	4.23e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PSMA4—liver cancer	2.57e-06	4.23e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PPARA—liver cancer	2.57e-06	4.22e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MAPK8—liver cancer	2.57e-06	4.22e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CYP1A1—liver cancer	2.56e-06	4.21e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IL6—liver cancer	2.54e-06	4.17e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GSTP1—liver cancer	2.51e-06	4.13e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CD—liver cancer	2.51e-06	4.12e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GOT2—liver cancer	2.5e-06	4.11e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—HMOX1—liver cancer	2.48e-06	4.07e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—ALB—liver cancer	2.48e-06	4.07e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CTNNB1—liver cancer	2.46e-06	4.04e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—MTHFR—liver cancer	2.41e-06	3.96e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CDKN1A—liver cancer	2.4e-06	3.95e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—MTHFR—liver cancer	2.39e-06	3.93e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—VEGFA—liver cancer	2.37e-06	3.9e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PPARA—liver cancer	2.36e-06	3.88e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CYP2E1—liver cancer	2.35e-06	3.87e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—STAT3—liver cancer	2.35e-06	3.86e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PPARA—liver cancer	2.34e-06	3.85e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—AKT1—liver cancer	2.34e-06	3.85e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—AKT1—liver cancer	2.33e-06	3.83e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CB—liver cancer	2.32e-06	3.82e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GSTM1—liver cancer	2.31e-06	3.8e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.31e-06	3.79e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CG—liver cancer	2.2e-06	3.62e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CYCS—liver cancer	2.2e-06	3.62e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CYP1A1—liver cancer	2.19e-06	3.6e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CB—liver cancer	2.19e-06	3.59e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MYC—liver cancer	2.18e-06	3.59e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TGFB1—liver cancer	2.18e-06	3.58e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GOT1—liver cancer	2.16e-06	3.55e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GGT1—liver cancer	2.16e-06	3.55e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—STAT3—liver cancer	2.14e-06	3.52e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PPARG—liver cancer	2.12e-06	3.49e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.1e-06	3.46e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—MTHFR—liver cancer	2.04e-06	3.35e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CG—liver cancer	2.02e-06	3.33e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—KRAS—liver cancer	2.02e-06	3.31e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CG—liver cancer	2.01e-06	3.3e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PPARA—liver cancer	2e-06	3.29e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MYC—liver cancer	1.99e-06	3.27e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—TGFB1—liver cancer	1.99e-06	3.26e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PPARG—liver cancer	1.95e-06	3.21e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GSTP1—liver cancer	1.94e-06	3.19e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PPARG—liver cancer	1.94e-06	3.18e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CD—liver cancer	1.93e-06	3.18e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—HMOX1—liver cancer	1.91e-06	3.14e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ALB—liver cancer	1.91e-06	3.14e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PIK3CA—liver cancer	1.85e-06	3.04e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—KRAS—liver cancer	1.84e-06	3.02e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.8e-06	2.96e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TP53—liver cancer	1.79e-06	2.95e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GSTM1—liver cancer	1.78e-06	2.93e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CD—liver cancer	1.78e-06	2.92e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CD—liver cancer	1.76e-06	2.9e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ALB—liver cancer	1.76e-06	2.89e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ALB—liver cancer	1.74e-06	2.86e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CG—liver cancer	1.71e-06	2.82e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—HRAS—liver cancer	1.71e-06	2.82e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PIK3CA—liver cancer	1.69e-06	2.78e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CYP1A1—liver cancer	1.69e-06	2.78e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CB—liver cancer	1.69e-06	2.77e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PPARG—liver cancer	1.66e-06	2.72e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—IL6—liver cancer	1.64e-06	2.7e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—MTHFR—liver cancer	1.58e-06	2.59e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—HRAS—liver cancer	1.56e-06	2.57e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CB—liver cancer	1.55e-06	2.55e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PPARA—liver cancer	1.55e-06	2.54e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CB—liver cancer	1.54e-06	2.53e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—AKT1—liver cancer	1.51e-06	2.49e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CD—liver cancer	1.51e-06	2.48e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—IL6—liver cancer	1.5e-06	2.46e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ALB—liver cancer	1.49e-06	2.45e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CA—liver cancer	1.42e-06	2.33e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—AKT1—liver cancer	1.38e-06	2.27e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CA—liver cancer	1.33e-06	2.19e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CG—liver cancer	1.32e-06	2.18e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CB—liver cancer	1.31e-06	2.16e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PPARG—liver cancer	1.28e-06	2.1e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CD—liver cancer	1.16e-06	1.91e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—AKT1—liver cancer	1.16e-06	1.9e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ALB—liver cancer	1.15e-06	1.89e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—AKT1—liver cancer	1.09e-06	1.79e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CA—liver cancer	1.03e-06	1.69e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CB—liver cancer	1.01e-06	1.67e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CA—liver cancer	9.46e-07	1.55e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CA—liver cancer	9.37e-07	1.54e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—AKT1—liver cancer	8.4e-07	1.38e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CA—liver cancer	8.01e-07	1.32e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—AKT1—liver cancer	7.72e-07	1.27e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—AKT1—liver cancer	7.66e-07	1.26e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—AKT1—liver cancer	6.54e-07	1.08e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CA—liver cancer	6.18e-07	1.02e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—AKT1—liver cancer	5.05e-07	8.3e-06	CbGpPWpGaD
